口服Xa因子直接抑制剂阿哌沙班的临床研究进展  

Development of clinical research on apixaban, an oral direct inhibitor of factor Xa

作　　者：王磊[1] 钟静芬[1] 时惠麟[1] 

机构地区：[1]上海医药工业研究院,上海200437

出　　处：《上海医药》2012年第17期17-20,共4页Shanghai Medical & Pharmaceutical Journal

摘　　要：阿哌沙班是口服Xa因子直接抑制剂,继达比加群酯和利伐沙班后上市,用于择期髋关节或膝关节置换手术的成年患者,以预防静脉血栓形成。本文主要介绍这个新药的研发背景、作用机制、药动学和临床试验。As an oral direct inhibitor of factor Xa, Apixaban is approved after dabigatran etexilate and rivaroxaban, which has been used for prevention of venous thromboembolic events in adult patients who have undergone elective hip or knee replacement surgery. This article discusses the discovery, mechanism, pharmacokinetics, and clinical trials of this emerging drug.

关 键 词：阿哌沙班 XA因子抑制剂 静脉血栓 

分 类 号：R96[医药卫生—药理学]